Objectives: Recent emergence of the extensively drug-resistant Neisseria gonorrhoeae H041 strain in Japan raises concerns that gonorrhoea may soon become untreatable and emphasizes the need for enhanced surveillance. In this study we developed a real-time PCR assay for direct detection of the H041 strain.
Introduction
The isolation of a highly ceftriaxone-resistant strain of Neisseria gonorrhoeae has recently been reported in Japan. 1, 2 In addition to having the highest MIC of the extended-spectrum cephalosporins reported, this N. gonorrhoeae H041 strain was resistant to several other antibacterials used to treat gonorrhoea, including penicillin, fluoroquinolones and macrolides, with the exceptions of spectinomycin and rifampicin. 2 The resistance profile exhibited by this strain reflects a culmination of emerging N. gonorrhoeae antimicrobial resistance (AMR) over several decades that unfortunately leaves few viable alternative treatment options. 3 Further spread or emergence of this extensively drug-resistant strain of N. gonorrhoeae in other parts of the world is of global concern. 4 Enhancing current AMR surveillance strategies to advance detection and understand the current distribution of the H041 strain is urgently required. In this study, two real-time PCR assays for detection of the H041 strain were developed and evaluated in parallel. Assay sensitivities and specificities were investigated using a panel of 
Materials and methods

H041 real-time PCR assays
Two real-time PCR assays, H041-PCR1 and H041-PCR2, were developed using Taqman probe technology. Primers and probe (Table 1) were designed using the Primer Express 2.0 software (Applied Biosystems Pty Ltd, Australia), based on the H041 penA sequence acquired through GenBank (accession no. AB546858). The reaction mixture for each assay consisted of 12.5 mL of QuantiTect Probe PCR Master Mix (Qiagen, Doncaster, Australia), 10.0 pmol each of forward and reverse primer (H041-F1 and H041-R for H041-PCR1 and H041-F2 and H041-R for H041-PCR2; Table 1 ), 4.0 pmol of H041-Probe (Table 1) and 2.5 mL of sample nucleic acid or control in a final reaction volume of 25.0 mL. Cycling was performed on a Rotor-Gene 6000 instrument (Qiagen, Australia) with the following conditions: initial hold at 958C for 15 min followed by 45 PCR cycles at 958C for 15 s and 608C for 60 s.
Positive controls
Nucleic acid from the H041 strain was not available for our initial experiments. Therefore, we developed 'Uni-Control' reactions to act as the positive control reactions for the H041-PCR1 and H041-PCR2 assays, using previously described methods. 5 Each Uni-Control comprised 16.0 pmol each of Uni-Control forward and reverse primers (H041-Unicontrol-F1 and H041-Unicontrol-R for the H041-PCR1 control and H041-Unicontrol-F2 and H041-Unicontrol-R for H041-PCR2; Table 1 ) and approximately one colony of a wild-type N. gonorrhoeae strain to act as the initiator template, and was made up to a total volume of 0.2 mL with water. This suspension was heat-denatured at 958C for 10 min and 2.5 mL of this suspension was then added to the PCR mixture. Briefly, the Uni-Control principle uses a low amount of the Uni-Control primers (0.2 pmol in the positive control PCR) to generate a small amount of PCR product by amplification of the initiator template; the Uni-Control primers described here target highly conserved regions on the N. gonorrhoeae penA gene, and therefore almost any gonococcal strain could be used as the initiator template. The Uni-Control primers are 5
′ tagged with the H041-PCR primer and probe sequences. Thus, extension of these sequences generates amplifiable material for the H041-PCR assays.
Assay validations
The performance of the methods was assessed in three stages: (i) the specificity of the H041-PCR1 and H041-PCR2 assays was initially investigated using a panel of Neisseria species (n¼167 strains), comprising both gonococcal and non-gonococcal isolates; (ii) specificity was further examined using DNA extracts from 252 clinical specimens submitted for sexual health screening-this testing was performed to Table 1 . List of primers and probes used in this study
Designation
Oligonucleotide sequence H041 primers and probe Clinical specimens (n¼252) N. gonorrhoeae positives (n¼59) urogenital (n ¼45) negative negative anal swabs (n¼8) negative negative throat swabs (n ¼6) POSITIVE (1) negative N. gonorrhoeae negatives (n ¼193) urogenital (n ¼143) negative negative throat swabs (n ¼50) POSITIVE (7) negative Neisseria gonorrhoeae H041 PCR 903 JAC investigate the potential for cross-reaction with other bacterial species/ strains that may be present in these specimens; and (iii) the detection limits of the assays were compared with a standard N. gonorrhoeae realtime PCR method.
Neisseria species
A total of 67 N. gonorrhoeae isolates were tested. These included: 37 genetically diverse gonococci of mainly Australian and Asian origin (years of isolation, 2000 -05) from a previous study, 6 comprising 29 different N. gonorrhoeae multi-antigen sequence types (NG-MAST) and 18 different penA types; 20 more recent clinical N. gonorrhoeae isolates from Sydney, Australia (year of isolation, 2010); 9 gonococci used as WHO reference cultures (WHO C, F, G, K, L, M, N, O and P); 7 and the N. gonorrhoeae H041 strain (n ¼1) 1,2 provided by the National Institute of Infectious Diseases, Japan. A panel of commensal Neisseria and other closely related species (n ¼100 strains) were also tested and are summarized in Table 2 .
Clinical specimens
The 252 clinical specimens included both N. gonorrhoeae-positive (n¼59) and N. gonorrhoeae-negative (n¼193) specimens. The N. gonorrhoeaepositive samples comprised DNA extracts from 39 specimens (25 urogenital, 8 anal and 6 throat swabs) submitted to Pathology Queensland in the period 2006-07 and providing N. gonorrhoeae-positive PCR results in a previous study 8 and a further 20 urogenital specimens testing positive by N. gonorrhoeae PCR at the South Eastern Area Laboratory Services in Sydney, New South Wales, in 2010.
The N. gonorrhoeae-negative specimens comprised DNA extracts of 193 specimens providing N. gonorrhoeae-negative results using four different PCR assays as part of a previous study. 8 These specimens were submitted to Pathology Queensland for N. gonorrhoeae screening in the period 2006 to 2007 and included 43 urine specimens, 86 cervical swabs, 14 vaginal swabs and 50 throat swabs.
Detection limit determination
A 10-fold dilution series (10E21 to 10E210) was prepared using DNA from the N. gonorrhoeae H041 strain. The dilutions were tested using both the H041-PCR1 and H041-PCR2 assays as well as an N. gonorrhoeae real-time PCR assay routinely used by our laboratory for detection of gonorrhoea and targeting the gonococcal porA pseudogene (porAmonoplex). 8 The detection limit of each assay was determined as the lowest concentration returning positive amplification.
Results
The PCR results for the isolates and clinical samples are summarized in Table 2 . Briefly, both the H041-PCR1 and H041-PCR2 assays correctly detected the N. gonorrhoeae H041 strain and provided negative results for all other N. gonorrhoeae strains. However, the H041-PCR1 cross-reacted with 2 of the 21 (10%) Neisseria subflava isolates and provided positive results for eight throat swab samples, seven of which were PCR-negative for N. gonorrhoeae. All of these H041-PCR1-positive results, including that from the N. gonorrhoeae-positive throat sample, were considered false-positive results in the H041-PCR1 assay on the basis that the majority of these samples (seven of eight samples) were N. gonorrhoeae-negative and all of these samples were from Queensland in the years 2006/2007, well before the emergence of the H041 strain in Japan in 2009. The H041-PCR2 assay was specific for the H041 strain, with no falsepositive results observed. The testing of 10-fold dilutions of DNA from the H041 strain showed that the porA pseudogene PCR, ...T.G...T........C.C........GC..........G..A.....C..A..T..G.CT..T..CA....C.....G..T. ..
H041-F2
. H041-PCR1 and H041-PCR2 assays had comparable detection limits, with all three assays detecting to the 10E27 dilution. The two N. subflava isolates were further investigated to determine the basis of the cross-reaction with the H041-PCR1 assay. Briefly, a 533 bp fragment of the penA genes for these isolates was PCR-amplified and DNA-sequenced using previously described primers (AAAACGCCATTACCCGATGGG and TAATGCCGCGCACATC CAAAG) 9 flanking the H041-PCR1 and H041-PCR2 assay targets. Sequence analysis revealed that the penA sequences from both N. subflava isolates were identical. When compared with the N. gonorrhoeae H041 strain (Figure 1) , the N. subflava strains had 76% homology with H041 for nucleotides 523-895, but 96% homology for nucleotides 896-1054. Notably, the primer and probe targets of the H041-PCR1 assay, which are located in the latter part of the sequence, had only one or two mismatches with these N. subflava strains. In contrast, the H041-F2 primer of the H041-PCR2 assay, at positions 835 -856, had seven mismatches across the primer. Of further interest was that both N. subflava strains possessed the Ala328Thr alteration previously only observed in the N. gonorrhoeae H041 strain.
Discussion
The N. gonorrhoeae ceftriaxone-resistant H041 strain was first isolated from the throat of a female commercial sex worker in Kyoto in January 2009. 1 To our knowledge, this strain has not been observed elsewhere, raising questions as to whether further or ongoing transmission is, or has been, occurring. Answering these questions is a public health priority given the extensive resistance profile exhibited by this strain, and is the reason underpinning the development of the above PCR methods. In this study we developed two H041 PCR assays targeting the gonococcal penA gene, which is the gene of most interest in conferring resistance to later-generation cephalosporins, including ceftriaxone. 2, 6, 9 Overall, the results of this study show that the H041-PCR2 assay, but not the H041-PCR1 assay, was both sensitive and specific for the H041 strain. The H041-PCR2 assay detected DNA from the H041 strain to a detection limit similar to that of a standard N. gonorrhoeae real-time PCR assay used by our laboratory and did not give any falsepositive results with any of the other isolates or clinical samples tested. Thus, the H041-PCR2 assay has considerable potential to be used to address questions relating to the current prevalence of the H041 strain.
The observed cross-reaction of the H041-PCR1 assay with the N. subflava strains in this study further highlights the recognized problems with gonococcal PCR assays, in that their specificity can be readily undermined via high homology or ongoing genetic exchange with commensal Neisseria species. 10 Nevertheless, it was interesting to note that both N. subflava strains harboured the Ala328Thr alteration, being one of four substitutions previously only observed in the N. gonorrhoeae H041 strain. However, as these strains were both isolated in Australia in 1996, this most likely reflects that, to date, there have been limited investigations of commensal penA sequences and that this alteration may be more common than previously thought.
Overall, our results show that the H041-PCR2 assay is capable of direct detection of the N. gonorrhoeae H041 ceftriaxone-resistant strain. In addition, this study highlights that, with the aid of DNA sequencing, PCR methods can be readily developed for the strain-specific detection of gonococci of public health importance, demonstrating the potential of such assays to enhance culturebased AMR surveillance. We are now using the H041-PCR2 assay in both retrospective and prospective studies in Japan to determine the prevalence of the H041 strain.
